T1	Participants 674 950	patients with locally advanced or metastatic NSCLC who were eligible for bevacizumab, excluding those with predominantly squamous histology. Patients were required to provide informed consent and to have initiated bevacizumab with chemotherapy within 4 months before enrollmen
T2	Participants 1167 1202	1967 patients with first-line NSCLC
T3	Participants 1274 1366	Median age was 65 years (range, 31-93), and 252 patients (12.8%) identified as never smokers
